OMCL stock sentiment todayOmnicell Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
OMCL
Omnicell IncOmnicell is navigating a painful transition from hardware-heavy sales to a SaaS-based recurring model amidst cautious hospital capital spending.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for OMCL. Not financial advice.
Price · last 12 months
Gossip
The narrative is centered on a 'reset' year. While long-term optimism exists for their 'Autonomous Pharmacy' vision, short-term chatter focuses on sluggish hospital budgets and the recent leadership shakeup (new CFO). Investors are waiting for proof that the XT series replacement cycle will actually trigger in 2025.
- ·Transition to recurring revenue subscription models
- ·Macro headwinds affecting healthcare capital expenditures
- ·Potential M&A target due to depressed valuation
- ·Implementation of cost-savings and restructuring plans
Financial
Revenue has been stagnant to declining as the company shifts away from upfront point-of-sale recognition. Balance sheet is manageable but leverage increased following the 2022-2023 downturn. Margins are currently compressed due to the service-mix shift and inflationary pressures.
- ·Negative 1-year revenue growth (~ -10%)
- ·Forward P/E in the 25x-30x range (high relative to growth)
- ·Positive but fluctuating Free Cash Flow
- ·Substantial deferred revenue growth indicating pipeline health
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Extended hospital sales cycles due to labor costs and interest rates
- ·Execution risk in the 'SaaS-ification' of the business model
- ·Intense competition from Becton Dickinson (Pyxis)
Peer temperature
How direct competitors stack up against OMCL right now.
- HOTBDXBecton, Dickinson and Company
HOTTER — Superior scale and diversified revenue streams make it a safer play with more consistent dividend growth compared to OMCL's volatility.
See full analysis → - NEUTRALBSYBentley Systems (Healthcare IT/Infra Context)
NEUTRAL — Similar valuation multiples but offers more predictable enterprise software margins than OMCL’s hardware-reliant mix.
See full analysis → - COLDCERNOracle (Cerner)
COLDER — While a giant in clinical data, the integration into Oracle has slowed specialized innovation where OMCL still maintains a niche edge in pharmacy automation.
See full analysis →
- OMCL+7.6%
- BDX+10.5%
- BSY+28.0%
- CERN—
Analyst price target
Consensus average of 5 analysts · median 60.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.